Area of research
Immunology · Oncology
Research interest
Research interests include Immune Cell Function and Interaction, Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, and T-cell and B-cell Immunology.
PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer
Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes
IL-17 induces antitumor immunity by promoting beneficial neutrophil recruitment and activation in esophageal squamous cell carcinoma
A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma
Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma
Interleukin-37 Mediates the Antitumor Activity in Hepatocellular Carcinoma: Role for CD57+ NK Cells
Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer
Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma
IL-17A Promotes Immune Cell Recruitment in Human Esophageal Cancers and the Infiltrating Dendritic Cells Represent a Positive Prognostic Marker for Patient Survival
The Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Therapy for Postoperative Hepatocellular Carcinoma Patients
Decreased Expression of the ARID1A Gene Is Associated with Poor Prognosis in Primary Gastric Cancer